Serologic Interpretation and Management of Coccidioidomycosis

Understanding the Serologic Pattern

• The Infectious Diseases Society of America recommends that IgM antibodies should decline as IgG antibodies rise during recovery, and the complement-fixing IgG antibody should increase and eventually predominate as the infection resolves, with titers expected to decrease gradually over months 1

Immediate Management Recommendations

• The American College of Physicians and the Infectious Diseases Society of America recommend continuing current antifungal therapy without interruption, with fluconazole 400 mg daily continued for a minimum of 3-6 months total, until signs, symptoms, inflammatory markers, serologies, and radiographs have stabilized 1, 2

Monitoring Strategy Over Next 2-4 Weeks

• The Infectious Diseases Society of America recommends repeating coccidioidal IgM and IgG/complement fixation antibody testing in 2-4 weeks, running the current specimen concurrently with the new specimen for comparative purposes, and obtaining erythrocyte sedimentation rate to assess systemic inflammation 1
• Clinical assessment for systemic symptoms and respiratory symptoms should be performed, and repeat chest radiography should be considered if symptoms are not clearly improving or if new symptoms develop 1, 3

Expected Serologic Evolution

• The Infectious Diseases Society of America notes that in a patient responding appropriately to treatment, IgM antibodies should be declining or becoming undetectable, and IgG/complement fixation antibodies should be present and either stable or beginning to decline 1
• The complement fixation titer provides prognostic information, with titers >1:16 suggesting more extensive disease requiring treatment 4

Red Flags Requiring Escalation

• The Infectious Diseases Society of America recommends evaluating immediately for complications if worsening respiratory symptoms, new focal symptoms outside the chest, or persistent/severe headaches develop, which may indicate disseminated disease 1, 3
• New skin lesions, joint effusions, or neurologic symptoms require tissue diagnosis and consideration of extrapulmonary dissemination 1, 4

Common Pitfalls to Avoid

• The Infectious Diseases Society of America advises against discontinuing antifungal therapy based solely on patient feeling better, and recommends that objective serologic and radiographic improvement must be documented 1
• The society also recommends against waiting for complete serologic normalization before discontinuing therapy, and against extending intervals between follow-up visits when serologies show an atypical pattern 1, 3